Measure | Pegloticase Biweekly | Pegloticase Monthly | Placebo |
---|---|---|---|
Patient global assessment | |||
N* | 50 | 57 | 35 |
N (%) final visit | 27 (54) | 29 (51) | 10 (29) |
p vs placebo** | 0.03 | NS | |
Pain | |||
N | 60 | 62 | 37 |
N (%) final visit | 33 (55) | 27 (44) | 14 (27) |
p vs placebo** | 0.01 | NS | |
Health Assessment Questionnaire-Disability Index | |||
N | 62 | 63 | 38 |
N (%) final visit | 28 (45) | 30 (48) | 6 (16) |
p vs placebo** | < 0.003 | < 0.001 | |
Physical Component Summary | |||
N | 58 | 62 | 38 |
N (%) Week 25 | 37 (64) | 38 (61) | 11 (29) |
p vs placebo** | < 0.01 | < 0.01 |